Aarey drugs & pharmaceuticals Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the mandatory certificate for the quarter ended March 31, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Filing

The company submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to both BSE Limited and National Stock Exchange of India Limited on April 14, 2026. The certificate was signed by Director Nimit Ghatalia (DIN: 07069841) on behalf of the company.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Share Transfer Agent. The registrar issued the compliance certificate on April 3, 2026, confirming proper handling of securities dematerialisation processes during the quarter.

The certificate confirms that securities received from depository participants for dematerialisation were properly processed within prescribed timelines. MUFG Intime verified that security certificates received for dematerialisation were mutilated and cancelled after due verification, with depositories' names substituted in the register of members as registered owners.

Corporate Information

Aarey Drugs & Pharmaceuticals Limited operates as a manufacturer of bulk drugs and importer of solvents and chemicals. The company maintains its head office at Sahakar Bhavan, Mumbai, with its registered office and factory located at MIDC, Tarapur, Boisar in Thane district.

The submission of this quarterly compliance certificate reflects the company's adherence to SEBI regulations governing depositories and participants, ensuring transparency in securities handling and maintaining investor confidence through proper regulatory compliance.

Aarey Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, showing a mixed performance with revenue declining year-on-year while maintaining profitability. The Board of Directors approved these results at their meeting held on February 11, 2026.

Financial Performance Overview

The company's financial performance for Q3FY26 reflects challenging market conditions with reduced revenue but sustained profitability:

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, also showed declining trends across key financial metrics:

Cost Structure and Operational Metrics

The company's cost management during Q3FY26 showed several notable changes. Cost of materials consumed decreased to ₹9,930.48 lakhs from ₹13,146.17 lakhs in the previous year quarter. Employee benefit expenses remained relatively stable at ₹14.57 lakhs compared to ₹18.02 lakhs in Q3FY25. Finance costs increased marginally to ₹91.91 lakhs from ₹90.05 lakhs year-on-year.

Capital Structure and Asset Investments

The company maintained its paid-up equity share capital at ₹2,845.43 lakhs with 28,454,303 shares of face value ₹10 each. A significant development during the reporting period was the purchase of certain fixed assets that are not yet ready for intended use. The company has not charged depreciation on these assets, which will commence once they are fully installed and commissioned in accordance with IND AS 16.

Regulatory Compliance and Audit

The financial results were prepared in accordance with Indian Accounting Standards and reviewed by independent auditors Motilal & Associates LLP. The Audit Committee reviewed the results before Board approval. The company operates in a single segment of manufacturing and trading of drugs and pharmaceuticals, with no separate reportable segments as defined by IND AS 108.